F-box protein 28Genealiases: CENP-30 · DEE100 · Fbx28
Q-omics provides the consensus-scored FBXO28 profile across patient tissues and cancer cell-line models. FBXO28 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FBXO28 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, FBXO28 RNA expression shows 20,835 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where FBXO28 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXO28 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXO28 survival associations across molecular data types. FBXO28 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXO28 RNA expression–survival associations across cancer types. High FBXO28 expression shows unfavorable associations in KIRP, ACC, UVM, PAAD and LUAD, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FBXO28 RNA expression.
This table summarizes FBXO28 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FBXO28. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXO28 shows lower tumor expression in KICH and higher tumor expression in HNSC, LUAD, KIRC, BRCA and BLCA. The HNSC box plot shows higher FBXO28 RNA expression in tumor versus normal tissue (log2 FC = +0.689, t-test p < 0.001).
This table shows molecular features associated with FBXO28 in patient tissues and cancer cell lines. In patient samples, FBXO28 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXO28 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
